Business UpdateJun 24, 2026, 06:17 AM
Takeda FY2025 Revenue $28.3B, EPS $3.25; Advances Pipeline
AI Summary
Takeda Pharmaceutical Co. Ltd. released its 2026 Annual Integrated Report for fiscal year 2025, highlighting solid financial performance with $28.3 billion in revenue and $3.25 core EPS. The company made significant progress on its pipeline, preparing to launch three new products in the next 12 months and advancing late-stage assets. Takeda also reported substantial reductions in Scope 1, 2, and 3 GHG emissions, demonstrating commitment to its net-zero ambition by FY2040, and invested significantly in CSR and community programs.
Key Highlights
- Reported FY2025 revenue of $28.3 billion and core earnings per share of $3.25.
- Preparing to launch three new products (oveporexton, rusfertide, zasocitinib) in the next 12 months.
- Achieved a 58% reduction in Scope 1 and 2 GHG emissions from FY2016 baseline.
- Reduced Scope 3 GHG emissions by 10% from FY2022 baseline, targeting 25% by FY2030.
- Committed $32.1 million in multi-year funding through its Global CSR Program.
- Invested $16.4 million in U.S. community partners, reaching nearly 8.1 million people.
- 63% of employees actively use generative AI tools, with 30,000 learning hours on digital skills.
- Expanded late-stage oncology pipeline through a strategic partnership with Innovent Biologics.
Price Impact
More from TAK